Gansu Longshenrongfa Pharmaceutical IndustryLTD Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Shuangxi Qian

Algemeen directeur

CN¥439.6k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.7yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.9yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (SZSE:300534) Looks Just Right With A 26% Price Jump

Oct 04

Gansu Longshenrongfa Pharmaceutical IndustryLTD (SZSE:300534) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Aug 29

CEO

Shuangxi Qian (39 yo)

1.7yrs

Tenure

CN¥439,600

Compensatie

Mr. Shuangxi Qian serves as General Manager and Director at Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd since March 10, 2023 and served as Deputy General Manager until August 2020.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Shuangxi Qian	GM & Director	1.7yrs	CN¥439.60k	geen gegevens
Qin Hui Yuan	Deputy GM	12yrs	CN¥468.40k	geen gegevens
Yaowu Chen	Deputy GM & Chief Engineer	3.9yrs	CN¥404.80k	0.014% CN¥ 394.1k
Rong Xiao	Accounting Supervisor	no data	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

42yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300534 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Shuangxi Qian	GM & Director	1.7yrs	CN¥439.60k	geen gegevens
Qin Hui Yuan	Deputy GM	7yrs	CN¥468.40k	geen gegevens
Yong Hong Kang	Vice Chairman	7yrs	CN¥515.50k	0.55% CN¥ 15.2m
Zongyi Li	Independent Director	3.9yrs	CN¥50.60k	geen gegevens
Zhen Luo	Independent Director	3.9yrs	CN¥50.60k	geen gegevens
Zhongxin Guo	Chairman of Supervisory Board	3.9yrs	geen gegevens	geen gegevens
Yijie Ren	Supervisor	5.7yrs	geen gegevens	geen gegevens
Bo Sun	Supervisor	3.9yrs	geen gegevens	geen gegevens
Ye Wu	Independent Director	less than a year	geen gegevens	geen gegevens
Rui Fu	Director	less than a year	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

45.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300534 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Gansu Longshenrongfa Pharmaceutical IndustryLTD Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD, Annual General Meeting, May 15, 2024

High number of new and inexperienced directors

High number of new directors

Gansu Longshenrongfa Pharmaceutical Industry CO. ,LTD, Annual General Meeting, May 13, 2022

Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd Announces Executive Appointments

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.011 (vs CN¥0.048 in 3Q 2023)

Investor sentiment deteriorates as stock falls 18%

Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (SZSE:300534) Looks Just Right With A 26% Price Jump

Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD to Report Q3, 2024 Results on Oct 23, 2024

Investor sentiment improves as stock rises 28%

Less than half of directors are independent

Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Approves Interim Cash Dividend for 2024

Gansu Longshenrongfa Pharmaceutical IndustryLTD (SZSE:300534) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD Proposes Interim Dividend for the First Half of 2024

Second quarter 2024 earnings released: CN¥0.002 loss per share (vs CN¥0.04 profit in 2Q 2023)

Now 21% undervalued after recent price drop

Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD to Report First Half, 2024 Results on Aug 23, 2024

Now 21% undervalued after recent price drop

Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd Announces Final Cash Dividend for 2023, Payable on 06 June 2024

Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD, Annual General Meeting, May 15, 2024

Full year 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.085 in FY 2022)

Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment deteriorates as stock falls 18%

Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD to Report Fiscal Year 2023 Results on Apr 24, 2024

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: CN¥0.048 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.04 (vs CN¥0.005 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.03 loss in FY 2021)

Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd (SZSE:300534) completed the acquisition of 70% stake in Gansu Pu'an Pharmaceutical Co.,Ltd. from Gansu Province Farms Agribusiness Ref co Group Ltd.

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.026 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.005 (vs CN¥0 in 2Q 2021)

Full year 2021 earnings released: CN¥0.03 loss per share (vs CN¥0.006 profit in FY 2020)

High number of new directors

Gansu Longshenrongfa Pharmaceutical Industry CO. ,LTD, Annual General Meeting, May 13, 2022

Gansu Longshenrongfa Pharmaceutical Industry CO. ,LTD to Report Fiscal Year 2021 Results on Apr 22, 2022

Third quarter 2021 earnings released: CN¥0.026 loss per share (vs CN¥0.007 loss in 3Q 2020)

Full year 2020 earnings released: EPS CN¥0.006 (vs CN¥0.042 in FY 2019)

Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥4.98

Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd Announces Executive Appointments

New 90-day low: CN¥5.85

New 90-day low: CN¥6.50

New 90-day high: CN¥8.41

Third quarter earnings released

Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd to Report Q3, 2020 Results on Oct 24, 2020

New 90-day high - CN¥7.68

First half earnings released

Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd to Report First Half, 2020 Results on Aug 22, 2020

New 90-day high - CN¥7.01

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd